Skip to main content
Clinical Trials/NCT02203812
NCT02203812
Completed
Phase 3

The Effect of Probiotic Lozenge Administration on Gingivitis and on Mild & Moderate Periodontitis: A Randomized Controlled Clinical Trial.

CD Pharma India Pvt. Ltd.1 site in 1 country32 target enrollmentJanuary 2015

Overview

Phase
Phase 3
Intervention
Probiotic Arm
Conditions
Mild and Moderate Chronic Periodontitis
Sponsor
CD Pharma India Pvt. Ltd.
Enrollment
32
Locations
1
Primary Endpoint
Improvement in Clinical Periodontal Indices
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The oral cavity is mostly influenced by general health. The oral microbiota which is as complex as the gastro-intestinal or vaginal microbiota are considered to be difficult therapeutic targets. The effects of probiotics in different fields of health care have resulted recently in the introduction of probiotics for oral healthcare. Probiotics have been clinically proved effective in different fields of oral healthcare such as halitosis, oral candidiasis and tooth decay. They have also been inducted in the field of periodontal healthcare because of the current views on the etiology of plaque- related periodontal inflammation.

Registry
clinicaltrials.gov
Start Date
January 2015
End Date
May 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients on probiotic supplements
  • Patients who have allergy to lactose and fermented milk products
  • Patients who are on antibiotic therapy or were on antibiotic therapy in the past 6 months
  • Patients with advanced periodontal and/or periapical conditions which necessitate immediate treatment
  • Patient suffering from any systemic illness
  • Patients who are deemed to be un-cooperative

Arms & Interventions

Probiotic Arm

L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.

Intervention: Probiotic Arm

Placebo Arm

Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).

Intervention: Placebo Arm

Outcomes

Primary Outcomes

Improvement in Clinical Periodontal Indices

Time Frame: 8 weeks

Improvement in clinical periodontal indices, namely, Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), Bleeding on Probing (BOP)

Secondary Outcomes

  • Improvement in Biochemical Indices(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials